Ewa LLC Grows Stake in Eli Lilly and Company $LLY

Ewa LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 35.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,172 shares of the company’s stock after acquiring an additional 571 shares during the period. Ewa LLC’s holdings in Eli Lilly and Company were worth $1,997,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter valued at $25,000. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the period. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $30,000. Finally, 10Elms LLP lifted its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to benefit from enthusiasm around its weight-loss and diabetes franchise, with articles highlighting its dominance in the GLP-1 market and expectations for further long-term growth. Article Title
• Positive Sentiment: The FDA selected Eli Lilly for its PreCheck pilot program, which could speed reviews of new U.S. manufacturing facilities and support Lilly’s multi-billion-dollar capacity expansion. Article Title
• Positive Sentiment: Investors also reacted to Lilly’s expanding oncology reach in China and the commercialization agreement for Verzenios, which keeps Lilly involved in supply and development while adding local distribution support. Article Title
• Positive Sentiment: Separately, Lilly was highlighted in several bullish commentary pieces after hitting record highs and new 52-week highs, reinforcing momentum in the shares. Article Title
• Neutral Sentiment: Cliff Asness’ AQR Capital Management listed Lilly among its top healthcare holdings, which may support investor confidence but is not a direct operational catalyst. Article Title
• Negative Sentiment: The main pressure point is the handoff of mainland China commercialization rights for Verzenios to Innovent Biologics, which investors may view as a reduction in direct control over part of Lilly’s China business and a reason for some near-term selling. Article Title

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,199.30 on Wednesday. The stock’s 50-day simple moving average is $1,048.18 and its 200 day simple moving average is $1,024.30. The stock has a market capitalization of $1.13 trillion, a price-to-earnings ratio of 42.60, a price-to-earnings-growth ratio of 1.35 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,238.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Leerink Partners boosted their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,235.07.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.